<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     caa a22        4500</leader>
  <controlfield tag="001">397592698</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20180308164943.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">161202e199605  xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1093/jac/37.suppl_B.97</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)oxford-10.1093/jac/37.suppl_B.97</subfield>
  </datafield>
  <datafield tag="100" ind1="1" ind2=" ">
   <subfield code="a">Wood</subfield>
   <subfield code="D">M. J.</subfield>
   <subfield code="u">Department of Infection and Tropical Medicine, Birmingham Heartlands Hospital, Birmingham B9 5SS, UK</subfield>
  </datafield>
  <datafield tag="245" ind1="1" ind2="0">
   <subfield code="a">Antivirals in the context of HIV disease</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
   <subfield code="c">[M. J. Wood]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">Antiviral drugs, other than those with anti-retroviral activity, are used in persons with human immunodeficiency virus (HIV) infection for two purposes: treatment or prevention of viral infections that cause disease in persons with immunodeficiency, and to suppress viruses that might act as co-factors and promote replication of HIV itself. Human herpesviruses are the major targets of therapy in both settings. The herpesviruses, particularly cytomegalovirus (CMV), herpes simplex virus (HSV) and varicella-zoster virus (VZV) act as opportunistic pathogens as cell-mediated immunity declines, and there is theorectical, in-vitro, and in-vivo evidence that one or more herpesviruses can accelerate the progression of HIV disease. Therapy and prophylaxis with antiherpes compounds such as acyclovir, ganciclovir and foscarnet are well established in HIV infection, and this article will review their present use and recent improvements in formulations and drug delivery.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">© 1996 The British Society for Antimicrobial Chemotherapy</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Articles</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
   <subfield code="t">Journal of Antimicrobial Chemotherapy</subfield>
   <subfield code="d">Oxford University Press</subfield>
   <subfield code="g">37(1996-05), 97-112</subfield>
   <subfield code="x">0305-7453</subfield>
   <subfield code="q">37&lt;97</subfield>
   <subfield code="1">1996</subfield>
   <subfield code="2">37</subfield>
   <subfield code="o">jac</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1093/jac/37.suppl_B.97</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">research-article</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1093/jac/37.suppl_B.97</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">100</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Wood</subfield>
   <subfield code="D">M. J.</subfield>
   <subfield code="u">Department of Infection and Tropical Medicine, Birmingham Heartlands Hospital, Birmingham B9 5SS, UK</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">773</subfield>
   <subfield code="E">0-</subfield>
   <subfield code="t">Journal of Antimicrobial Chemotherapy</subfield>
   <subfield code="d">Oxford University Press</subfield>
   <subfield code="g">37(1996-05), 97-112</subfield>
   <subfield code="x">0305-7453</subfield>
   <subfield code="q">37&lt;97</subfield>
   <subfield code="1">1996</subfield>
   <subfield code="2">37</subfield>
   <subfield code="o">jac</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="a">Metadata rights reserved</subfield>
   <subfield code="b">CC BY-NC-4.0</subfield>
   <subfield code="u">http://creativecommons.org/licenses/by-nc/4.0</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-oxford</subfield>
  </datafield>
 </record>
</collection>
